Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;47(4):280-287.
doi: 10.1111/jvp.13430. Epub 2024 Feb 9.

The effects of food on the pharmacokinetics of mycophenolate mofetil in healthy horses

Affiliations

The effects of food on the pharmacokinetics of mycophenolate mofetil in healthy horses

Kaitlyn Bello et al. J Vet Pharmacol Ther. 2024 Jul.

Abstract

Additional immunomodulatory treatment is needed for the management of immune-mediated disease in horses. Mycophenolate mofetil (MMF) is an immunomodulatory agent used in human and veterinary medicine for the prevention of graft rejection and the management of autoimmune diseases. Few studies exist investigating the pharmacokinetics of MMF in horses. The aim of this study was to evaluate the pharmacokinetics of a single dose of MMF in healthy horses in the fed vs. fasted state. Six healthy Standardbred mares were administered MMF 10 mg/kg by a nasogastric (NG) tube in a fed and fasted state. A six-day washout period was performed between the two doses. No statistically significant differences in mycophenolic acid (MPA) concentrations were seen at any time point apart from 8 h, when plasma metabolite concentrations were significantly higher in the fasted state compared to the fed state (p = .038). Evidence of enterohepatic recirculation was seen only in the fasted state; this did not yield clinical differences in horses administered a single-dose administration but may be significant in horses receiving long-term MMF treatment.

Keywords: equine; fed vs. fasted; immune‐mediated; mycophenolate mofetil; pharmacokinetics.

PubMed Disclaimer

References

REFERENCES

    1. Abd Rahman, A. N., Tett, S. E., & Staatz, C. E. (2013). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clinical Pharmacokinetics, 52(5), 303–331. https://doi.org/10.1007/s40262‐013‐0039‐8
    1. Allison, A. C. (2005). Mechanisms of action of mycophenolate mofetil. Lupus, 14, S2–S8. https://doi.org/10.1191/0961203305lu2109oa
    1. Amstutz, K., Schwark, W. S., Zakharov, A., Gomez, B., Lyubimov, A., Ellis, K., Venator, K. P., & Wakshlag, J. J. (2022). Single dose and chronic oral administration of cannabigerol and cannabigerolic acid‐rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. Journal of Veterinary Pharmacology and Therapeutics, 45(3), 245–254. https://doi.org/10.1111/jvp.13048
    1. Baggot, J. D. (1992). Bioavailability and bioequivalence of veterinary drug dosage forms, with particular reference to horses: An overview. Journal of Veterinary Pharmacology and Therapeutics, 15(2), 160–173. https://doi.org/10.1111/j.1365‐2885.1992.tb01003.x
    1. Bermingham, E., Davis, J. L., & Whittem, T. (2020). Study design synopsis: Designing and performing pharmacokinetic studies for systemically administered drugs in horses. Equine Veterinary Journal, 52(5), 643–650. https://doi.org/10.1111/evj.13312

Publication types

LinkOut - more resources